Hi-CRATES CO.,LTD.

As of the end of September 2025, the company had 2,974 customers. It has established an overwhelming position in western Japan, with a market share of 35.2% in the Shikoku block and 24.7% in the Chugoku block. The replacement/renewal rate over the past five years has reached 91.1%, and there are also many customers with long-term relationships exceeding 20 years. Free support based on the "Software San-mushugi" (three-no policy) principle underpins customer loyalty.

In FY2025 (ending September 2025), net sales were ¥2,407 million (up 13.9% year on year) and operating profit was ¥550 million (up 30.2% year on year), marking a record profit for the second consecutive period. The operating margin was 22.8%, the ordinary profit margin was 27.1%, and the equity ratio stood at a high level of 88.9%, indicating strong financial soundness. The company is debt-free and holds cash and cash equivalents of ¥1,104 million.

Through collaborative innovation with Hitachi, Ltd. on AI voice recognition technology, the company has rolled out three products: "AI/Voice Electronic Medical Record Integrated System Revo.11," "AI/Voice Periodontal Precision Examination," and "AI/Voice Sub-Chart." At clinics that have adopted these early, results have been confirmed such as enabling periodontal precision examinations to be completed by a single person, reducing examination time by 10 minutes, increasing maintenance rates by up to 12%, and tripling productivity.

Centered on the "AI/Voice Electronic Medical Record Integrated System Revo.11," "AI/Voice Periodontal Precision Examination," and "AI/Voice Sub-Chart," the company is promoting new customer acquisition and upselling to existing customers through awareness activities such as web seminars (briefings on the FY2026 medical fee schedule revision) and exhibitions at dental shows. Record-high profit was achieved in the interim period of FY2026 (ending September 2026), reflecting the effects of the sales expansion.

The company positions the major medical fee schedule revision—centered on preventive dentistry, home-visit care, and strengthened medical-dental collaboration—as "a major turning point that will fundamentally change the nature of dental care," and is strengthening the appeal of products and features that address it. Web seminars held in February and March raised awareness of the details of the revision, aiming to stimulate capital investment demand among dental clinics.

The company is promoting product development that supports the development of medical information infrastructure, including the electronic prescription management service and the electronic medical record information sharing service. While other companies' products face challenges such as in-house prescription support and additional costs, the company aims to highlight the superiority of its own products and establish itself as a core vendor driving medical DX.

The company has set targets for FY2030 (ending September 2030) of net sales of ¥4,000 million, ordinary income of ¥1,200 million, net income of ¥800 million, an ordinary income margin of 30%, and a net income margin of 20%. Achieving the full-year forecast for FY2026 (ending September 2026) of net sales of ¥2,484 million and ordinary income of ¥662 million—record-high profit for the third consecutive term—will serve as a stepping stone toward these medium- to long-term targets.